DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer
Safety results were generally consistent with known individual profiles for T-DXd and combination drugs. T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Danielle Carroll
- Cuihong Zhang (ORCID: https://orcid.org/0000-0001-7247-7746)
- CK Anders
- Magdalena Wrona (ORCID: https://orcid.org/0000-0003-1095-4660)
- Robyn R. Young (ORCID: https://orcid.org/0000-0003-4466-8240)
- Loi Sherene
- Komal Jhaveri
- Caron Lloyd
- L. Testa
- Seock-Ah Im
- Fabrice Andre
- Yeon Hee Park
- Peter Schmid
- Yen-Shen Lu
- Shin-Cheh Chen
- Hans Wildiers
- Ling-Ming Tseng
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- National Yang Ming Chiao Tung University (TW)
- Queen Mary University of London (GB)
- Cancer Research Institute (US)
- Cornell University (US)
- Université Paris-Saclay (FR)
- Peter MacCallum Cancer Centre (AU)
- Institut Gustave Roussy (FR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Taipei Veterans General Hospital (TW)
- Chang Gung Memorial Hospital (TW)
- Sarah Cannon (US)
- D’Or Institute for Research and Education (BR)
- Center for Cancer and Blood Disorders (US)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- Linkou Chang Gung Memorial Hospital (TW)
- Duke Medical Center (US)
- National Taiwan University Hospital (TW)
- Tennessee Oncology (US)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Spain) (ES)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0874
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Memorial Sloan-Kettering Cancer Center
- Astex Pharmaceuticals
- Eisai
- Daiichi Sankyo Europe